Wednesday, January 11, 2023 10:32:20 AM
4:05 pm ET January 4, 2023 (Globe Newswire) Print
GlobeNewswireJanuary 04, 2023
SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors.
"We are thrilled to have Jill join the Oncternal board of directors. Jill's accomplishments building a multi-billion dollar oncology business in the U.S. are a great fit for supporting Oncternal's transition into a late-stage oncology company," said James Breitmeyer, M.D., Ph.D., Oncternal's President and CEO. "As we embark into our first global Phase 3 registrational study Zilo-301, we will greatly benefit from her guidance to help us build a compelling patient-centric value proposition for Zilovertamab."
Ms. DeSimone was most recently President of U.S. Oncology at Merck & Co., Inc., where she built the company's oncology division, growing it to over a $9 billion business in just eight years. She led three key product launches and more than 45 indication launches, including Keytruda(R). Prior to joining Merck, she served as senior vice president of Global Women's Health at Teva Pharmaceutical Industries Ltd from 2012 to 2014. Prior to her time at Teva, Ms. DeSimone served in several roles of increasing responsibility at Bristol Myers Squibb from 1980 to 2012, including senior vice president of U.S. Oncology & Commercial from 2010 to 2012 and senior vice president of U.S. Virology/HIV from 2006 to 2010. Ms. DeSimone currently serves as a member of the board of directors of Praxis Precision Medicines, Inc. and Affini-T Therapeutics Inc. She also serves as a board member for the Florida Cancer Specialists Foundation, a nonprofit organization that delivers non-medical aid for individuals undergoing cancer treatment. Ms. DeSimone received a B.S. in pharmacy from Northeastern University and completed a fellowship with the Wharton School of the University of Pennsylvania.
"I am honored to join the board at Oncternal, as it continues to advance its first-in-class late-stage oncology pipeline," said Ms. DeSimone. "I believe Zilovertamab and ROR1 can play a key role in addressing significant unmet needs in hematological malignancies and solid tumors, and I look forward to working with the board at Oncternal to continue to bring important therapeutic innovations to patients."
Recent ONCT News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/08/2024 09:42:09 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:20:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:10:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 10:02:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 11:00:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 11:00:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 11:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:05:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:00:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:00:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:00:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/05/2024 09:00:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 09:00:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:15:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:31:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:01:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 08:59:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/04/2023 08:59:06 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 09/14/2023 08:01:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:30:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:11:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2023 10:59:18 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM